SynAffix Appoints World Leading Experts To Scientific Advisory Board And Recruits Chairman To Board Of Directors
AMSTERDAM--(BUSINESS WIRE)--Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced the appointment of a panel of industry experts to its inaugural scientific advisory board (SAB). Concurrent with the launch of the SAB, Synaffix has appointed Dr. Konstantinos Efthymiopoulos as the independent chairman of its Board of Directors.